Familial Pancreatic Cancer and Surveillance of High-Risk Individuals
- Author:
Hiroyuki MATSUBAYASHI
1
;
Kyoichi TAKAORI
;
Chigusa MORIZANE
;
Yoshimi KIYOZUMI
Author Information
- Publication Type:Review
- Keywords: Familial pancreatic cancer; High risk; Genetic; Surveillance; Treatment
- MeSH: Asian Continental Ancestry Group; Drug Therapy; Genetic Background; Humans; Pancreatic Neoplasms; Platinum; Registries; Risk Factors
- From:Gut and Liver 2019;13(5):498-505
- CountryRepublic of Korea
- Language:English
- Abstract: Family history of pancreatic cancer (PC) is a risk factor for PC development, and the risk level correlates with the number of affected families. A case of PC with ≥1 PC cases in the first-degree relative is broadly defined as familial pancreatic cancer (FPC) and accounts for 5% to 10% of total PC cases. FPC possesses several epidemiological, genetic and clinicopathological aspects that are distinct from those of conventional PCs. In Western countries, FPC registries have been established since the 1990s, and high-risk individuals are screened to detect early PCs. For the pharmacotherapy of FPC, especially in cases with germline pathogenic BRCA mutations, regimens using platinum and poly (ADP-ribose) polymerase inhibitor have recently been studied for their effectiveness. To date, the concept of FPC has prevailed in Western countries, and it has begun to infiltrate into Eastern countries. As the genetic background and environmental conditions vary in association with ethnicity and living area, we need to establish our own FPC registries and accumulate data in Asian countries.
